Fig. 3: Changes in the mobility of Halo-tagged HER2 on the surface of HEK293 cells upon treatment with DARPins and mAbs, quantified by FRAP.
From: Apoptosis-inducing anti-HER2 agents operate through oligomerization-induced receptor immobilization
a, b Confocal images from a representative FRAP experiment of HT-HER2 labeled with Alexa Fluor 660, by photobleaching either a in the equatorial (eq.) or b basal (bs.) membrane plane. The arrow indicates the location of the bleach spot (2 µm diameter). c, d FRAP curves (bleach-corrected, normalized mean fluorescence intensities in the bleached ROI after subtraction of residual intensity at t = 0) for various DARPin and antibody treatments and controls. c Massive reduction of mobility upon treatment with DARPin 6L1G. Data from the basal membrane are shown in addition to those obtained by regular measurements in the equatorial plane. d Slight reduction in mobility is seen upon treatment with the therapeutic mAbs PZB and TZB individually but complete immobilization by their combination (PZB + TZB). Untr., untreated.
